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According to the authors, the guidelines contains the 
most justified principles of diagnostic and therapeutic 
procedures. They should, however, be interpreted in 
the context of the individual clinical situation. Recom-
mendations do not always correspond to the current 
refund rules in force in Poland. In case of doubt, you 
should be sure of the current refund possibilities of 
each procedure.
Soft tissue sarcomas
Significant progress in the management of soft tis-
sue sarcoma (STS), which has occurred in the primary 
treatment and in management of recurrent disease, is 
the result of multidisciplinary treatment administered in 
specialised centres. The combination of surgical treat-
ment (primary method of therapy) with radiotherapy 
(RTH) and sometimes chemotherapy (CTH), and reha-
bilitation is a standard procedure that should be planned 
and carried out by multidisciplinary teams. The chances 
of limiting the range of resection and gaining long-term 
survival or cure are significantly increased. Modern com-
bination therapy, including reconstructive procedure, 
allows the limb to be saved in the majority of patients 
with STS limb location (in reference centres amputation 
is done currently in less than 10% of patients). There is 
a steady but slow increase in the percentage of patients 
with STS with long-term survival (the current five-year 
survival rate for STS with limb localisation is 55–78%). 
The prognosis at the metastatic stage of the disease is 
still poor (median survival approx. 12–15 months).
Positive local results only apply to patients with STS 
after scheduled (previous biopsy) complete primary tu-
mour excision (microscopically free of cancer) (resection 
R0). In the case of correct diagnosis, most patients after 
complete resection require the use of complementary 
RTH and multi-week rehabilitation and follow-up for at 
least five years in the treatment centre. Improvements in 
the prognosis of patients are also a result of the introduc-
tion of drugs that target molecular or genetic alterations 
involved in STS aetiopathogenesis.
Current recommendations are useful in the treat-
ment of STS for all locations in adults. Gastrointestinal 
stromal tumours (GIST) have been described separately.
Epidemiology and aetiology
In Poland, STS accounts for about 1% of all malig-
nant neoplasms in adults (4–5 cases per 100,000, about 
1000 cases per year) [1–3]. Most STS are sporadic. 
The greater incidence of STS is associated with certain 
genetic disorders (e.g. NF1 and NF2, Li-Fraumeni 
syndrome, Gardner syndrome, Werner syndrome), 
predisposing conditions (e.g. chronic lymphoedema 
— Stewart-Treves syndrome), with immunosuppres-
sion and environmental factors (e.g. past irradiation or 
exposure to herbicides, pesticides, polyvinyl chloride, 
and dioxins) [1, 2].
Diagnostics
Symptoms and physical examination
Anatomical locations of STS include: limbs (approx. 
50%), peritoneal cavity (approx. 20%), retroperitoneal 
space (approx. 15%), head and neck region (approx. 
10%), and other locations (approx. 5%). The clinical 
picture of STS is similar in many histological types, 
despite their significant differences.
In most cases, the only symptom of STS is a pain-
less tumour, most commonly located under the fascia. 
Confirmation of the position under the fascia authorises 
the initial suspicion of STS, regardless of the size of the 
tumour, and the diagnosis can only be established on 
the basis of the results of microscopic examination. Soft 
tissue sarcomas located above the fascia may infiltrate 
the skin (infiltration of the bone, fascia, muscles, and 
nervous structures is rare). More aggressive STS can 
exceed natural barriers. The size of the sarcoma at the 
time of diagnosis is often related to its anatomical loca-
tion. Particular interest should be paid to rapid (a few 
months) development of lesions larger than 10 cm or 
“acceleration” of growth, which may indicate a signifi-
cant biological aggressiveness of the tumour. Alleged 
bag (“pseudocapsule”) — reaction to pressure — is not 
an actual STS increase border. STS have a characteris-
tic tendency to spread, mainly by blood (primarily the 
lungs), and (rarely) by the lymphatic nodes. In the case 
of a retroperitoneal or intraperitoneal site, the sarcoma 
may cause pain associated with compression or lead to 
acute complications such as obstruction, bleeding, or 
perforation of the gastrointestinal tract.
Imaging studies
Imaging studies are performed during the first 
period of diagnosis (Figure 1) to assess local tumour 
progression and biopsy design and disease progres-
sion analysis, differentiating and setting indications 
for radical surgical treatment. Imaging studies include 
the following:
 — X-ray of the affected lesions — differentiation of 
deep-lying STS from primary bone sarcoma with 
secondary soft tissue infiltration and bone infiltra-
tion assessment and visualisation of calcifications 
characteristic for some types of STS;
 — chest X-ray (projections posteroanterior and lat-
eral) or computed tomography (CT) of the lungs 
and chest — exclusion of metastases in their most 
common location (STS with a high degree of histo-
logical malignancy);
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Figure 1. Diagnostic procedures for soft tissue sarcomas
 — magnetic resonance (MR) with the intravenous 
administration of contrast — the study of choice in 
the evaluation of STS located in the limb and trunk, 
enables precise distinction of neurovascular struc-
tures, and in the sagittal and frontal area — allows 
the three-dimensional imaging of muscle compart-
ments. MR is not very accurate in assessing the 
possible infiltration of bone by STS (the alternative 
is a spiral CT with contrast);
 — spiral CT with contrast given intravenously and to the 
gastrointestinal tract — basic evaluation method for 
retroperitoneal and intraperitoneal STS. In certain 
types of STS it allows further evaluation, for exam-
ple of lymph nodes in epithelioid sarcoma, synovial 
sarcoma, or clear cell sarcoma and abdominal cavity 
in myxoid/round cell liposarcoma.
Pathological assessment
After the imaging studies a biopsy should be planned 
and performed by an experienced surgical oncologist 
in collaboration with a radiologist and pathologist in 
a reference cancer centre.
The basis for the diagnosis and assessment of prognosis 
in STS is the result of histological examination of material 
obtained as a result of the diagnostic biopsy. The biopsy 
determines the proper treatment plan. It should be per-
formed in a way that does not adversely affect local radical 
treatment. The basic method of collecting the material 
is a needle aspiration biopsy (multiple tissue extraction 
with a needle ≥ 14–16 G) and possibly an open-cut biopsy. 
The site of the biopsy is cut out during radical surgery. 
An excision biopsy can be used only in the case of su-
perficial STS of size up to 5 cm. It is often equivalent to 
“enucleation” of the tumour and contraindicated in the 
event of all the soft tissue tumours having a size greater 
than 5 cm and/or located under fascia, because it prevents 
proper pre-treatment and results in surrounding residual 
microscopic foci of tumour tissues and changes the com-
partmental location of STS. Closed biopsy is associated 
with a slightly higher percentage of diagnostic errors 
than open biopsy, while open biopsy is associated with 
a greater number of complications. It is recommended that 
a portion of the biopsy tissue be protected for cytogenetic 
studies and frozen to allow molecular testing.
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In the optimal treatment regimen, diagnostic biopsy, 
correct microscopic diagnosis, and radical treatment 
should be performed in the same centre. Errors in diag-
nosis, poor uptake of the material, bad biopsy technique, 
unrepresentative biopsy, and complications of biopsy, 
which affect the change planned treatment or change in 
the course of the disease, occur more frequently when 
the test is carried out in less experienced centres, com-
pared with the reference centres [III, A]. The current 
proposals are as follows:
 — diagnostic biopsy (core needle or slitting) should be 
performed by a surgeon experienced in the treatment 
of sarcomas, who then will operate on the patient;
 — if the facility is not prepared for the use of combi-
nation therapy, the patient should be referred to 
the referral centre before biopsy. STS microscopic 
diagnosis must be established before determining the 
strategy of combination therapy based on diagnostic 
biopsy (not performing biopsy is a mistake) and must 
precede the radical management of the STS.
Diagnosis and treatment of STS in reference centres 
should concern patients with:
 — each soft tissue tumour located under the fascia, 
regardless of size;
 — each subcutaneous tumour of the largest size of 
more than 5 cm;
 — each soft tissue tumour suspected of malignancy.
Histological diagnosis should be based on World 
Health Organisation (WHO) classification [4] and 
histological malignancy assessment according to the 
Fédération Nationale des Centers de Lutte Contre 
Cancer (FNCLCC) [1]. Morphological and immuno-
histochemical evaluations should be complemented 
by molecular biology studies by in situ hybrid fluores-
cence (FISH) and a reverse transcriptase-polymerase 
chain reaction (RT-PCR) and, where possible, cy-
togenetic studies. The results of cytogenetic studies 
have revealed recurrent and non-random (specific) 
chromosomal aberrations leading to the formation 
of fusion genes in T-sarcomas (translocation-related 
sarcomas). The protein products of these fusion genes 
simultaneously act as oncoproteins that stimulate cell 
proliferation and transcription factors that determine 
the differentiation of sarcoma cells (specific transloca-
tions occurring in the most common T-sarcomas and 
the genes involved in the formation of specific fusion 
genes are shown in Tab. 1). 
A precondition for the creation of these fusion genes 
is the earlier break in the two genes involved in the 
formation of a specific fusion gene. This phenomenon 
is used to diagnose selected STS using FISH by means 
of break-apart probes (Tab. 1). FISH tests using these 
probes can be performed on tissue sections fixed in 
formalin and embedded in paraffin blocks. 
The pathological report of the postoperative mate-
rial in the part of the macroscopic description should 
include: exact location of the tumour (skin, subcutane-
ous tissue, soft tissue under superficial fascia), macro-
scopic description of the tumour with three dimensions, 
macroscopic characteristics (macroscopic image — fat, 
mucus, fibrous), description of tumour areas deviating 
from the typical appearance, extent of necrosis, and 
width of surgical margins in mm. The basic information 
of the microscopic part of the histopathological report 
is as follows: histological classification of tumours with 
malignancy grade, number of mitoses, extent of necro-
sis, and distance of tumour from surgical margins to 
surgical specimen (in mm); attention should be paid if 
tumour-free tissue margin extending in a tight fascia is 
satisfactory (margin < 2 mm in the soft tissues is insuf-
ficient, which should be explicitly noted in histopatho-
logy report).
Prognostic factors and staging
Prognostic factors are the basis for assessing the 
severity of the disease and planning for appropriate 
treatment. The most important factors affecting the 
prognosis in patients with sarcoma are:
 — degree of histological malignancy (G, grading);
 — the size of the primary tumour;
 — tumour localisation (under or over fascia);
 — presence of metastases;
 — the state of the surgical margin;
 — occurrence of recurrence.
Staging is essential in determining the prognosis 
and choosing the right method of treatment and in 
order to make a meaningful comparison of results be-
tween different centres and establish uniform criteria 
for clinical trials. Criteria for the proper assessment 
of the stage are provided by subject, imaging, and 
histological evaluation of the surgical material. At 
present, the modified system of the American Joint 
Committee on Cancer (AJCC)/International Union 
for Cancer (UICC Union Internationale Contre le 
Cancer) of 2010 (ed. 7) is used [6] — classification 
is based on tumour size (T1: ≤ 5 cm and T2: > 5 cm) 
and localisation (a — superficial or b — deep, or 
sub-fascial) and the presence or absence of me-
tastasis lymph nodes and distal organs (features 
N and M). Grades I–III describe STS localised or 
metastatic to regional lymph nodes, and Stage IV 
refers to metastatic disease (Tab. 2). The system 
according to the AJCC is not used in the staging of 
fibromatosis, also deep (desmoid), STS, and GIST 
derived from brain dura, parenchymal organs, or 
those having lumen (digestive tract, respiratory 
system). In revision 8 of the AJCC GTNM system, 
which will apply from 2018, a separate classification 
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Table 1. Specific types of translocations and gene fusions created in the selected soft tissue sarcomas (modified from [5])
Histological subtype of 
sarcoma
   Type of translocation         Fusion gene Gene used in FISH*
Myxoid liposarcoma t(12;16)(q13;p11)
t(12;22)(q13;q12)
FUS/DD1T3
EWSR1/DD1T3
DD1T3 (CHOP), FUS, 
EWSR1
Synovial sarcoma t(X;18)(p11;q11)  
t(X;18)(p11;q11)  
t(X;18)(p11;q11)  
t(X;20)(p11;q13)
SS18/SSX1
SS18/SSX2
SS18/SSX4
SS18L/SSX1
SS18 (SYT)
Alveolar rhabdomyosarcoma t(2;13)(q35;q14) t(1;13)(p36;q14)  
t(X;2)(q13;q35) t(2;2)(q35;p23)
PAX3/FOXO1A PAX7/FOXO1A 
PAX3/AFX PAX3/NCOA1
FOXO1A (FKHR), 
NCOA1
Ewing’s sarcoma/PNET t(11;22)(q24;q12)  
t(21;22)(q22;q12)  
t(7;22)(p22;q12) t(17;22)(q12;q12)  
t(2;22)(q33;q12)  
t(2;22)(q31;q12) t(16,21)(p11;q22)  
t(2,16)(q35;p11)
EWSR1/FLI1
EWSR1/ERG EWSR1/ETV1
EWSR1/ETV4
EWSR1/FEV EWSR1/SP3
FUS/ERG FUS/FEV
EWSR1
Clear cell sarcoma t(12;22)(q13;q12)
t(2;22)(q33;q12)
EWSR1/ATF1
EWSR1/CREB1
EWSR1
Low-grade fibromyxoid sarcoma t(7;16)(q34;p11)
t(11;16)(p11;p11)
FUS/CREB3L2
FUS/CREB3L1
FUS, CREB3L1, 
CREB3L2
Dermatofibrosarcoma 
protuberans
t(17;22)(q22;q13) COL1A1/PDGFB PDGFR-COL1A1
Extraskeletal myxoid 
chondrosarcoma
t(9;22)(q22;q12) EWS-CHN(NR4A3) EWSR1
Clear cell sarcoma t(12;22)(q13;q12) EWS-ATF1 EWSR1
Alveolar soft part sarcoma t(X;17)(p11.2;q25) ASPL-TFE3 TFE3
*Genes used in FISH studies using commercially produced break-apart probes; PNET — primitive neuroectodermal neoplasms
Only some of the genes for which rearrangements are used in diagnostic tests are included in the table. Probes are available commercially for the identification 
of almost all T-sarcomas, as well as parts of connective tissue hyperplasia, which are not malignant but may mimic sarcoma (e.g. nodular fasciitis, lipoblastoma)
Table 2. Clinical stage of soft tissue sarcoma by the American Joint Committee on Cancer/Union Internationale Contra 
le Cancer (AJCC/UICC) 2010* [6]
G T N M OS
IA, B G1 T1a, b; T2a, b N0 M0 About 90%
IIA, B G2–3
G2
T1a, b
T2a, b
N0 M0 About 70%
III G3
Any G
T2a, b
Any T
N0
N1
M0 About 50%
IV Any G Any T Any N M1 < 15%
T — tumour size (T1: tumour with maximal diameter ≤ 5 cm; T2: tumour with maximal diameter > 5 cm); a — superficial location (above the fascia-superficial 
without infiltration); b — deep location (sub-fascial, also retroperitoneal, mediastinal, pelvic); N — regional lymph nodes (N0 — absence of metastases, 
N1 — presence of metastases); M — metastases in distant organs (M0 — absence of metastases, M1 — presence of metastases); G — histological malig-
nancy (G1 — low = STS well differentiated; G2 — indirect = STS median; G3 — high = STS poorly differentiated/undifferentiated); OS — estimated five-year 
overall survival
*UICC/AJCC Grading System includes the following types of soft tissue sarcoma: alveolar soft-part sarcoma, desmoplastic small round cell tumour, dermatofi-
brosarcoma protuberans, epithelioid sarcoma; clear cell sarcoma; extraskeletal chondrosarcoma; extraskeletal osteosarcoma; Ewing’s sarcoma; fibrosarcoma; 
leiomyosarcoma; liposarcoma, malignant fibrous histiocytoma; malignant haemangiopericytoma; malignant peripheral nerve sheath tumour; rhabdomyo-
sarcoma; synovial sarcoma; angiosarcoma; sarcoma not otherwise specified
186
OncOlOgy in clinical practice 2017, Vol. 13, No. 5
for sarcoma located in the retroperitoneal space 
(nomogram) is included; inside the abdominal cav-
ity and the thoracic organs, and within the head 
and neck [7].
Treatment
The treatment of patients with STS is governed 
by the principle of multi-specialist therapy planning, 
including possible adjuvant treatment (pre- or post-
operative RTH and/or CTH), necessitating treatment 
at specialized centres by diagnostic and therapeutic 
teams (consisting, at least, of a pathologist, radiologist, 
oncologist, radiotherapist, and clinical oncologist, and 
rehabilitation) [III, A].
Surgical treatment
The primary goal in treating sarcoma is to provide lo-
cal disease control. Persistent cure can only be achieved 
by radical surgical treatment of the primary lesion, and 
in the case of metastases only by means of their radical 
surgical removal. The type of surgical treatment depends 
on many factors (such as the location and size of the 
tumour, the infiltration of the surrounding structures, 
and the need for reconstructive techniques). Aggres-
sive treatment of STS located on the limbs and the use 
of reconstructive techniques now allow the limb to be 
saved in most patients. The ability to reduce the risk of 
recurrence (local recurrence) to less than 20% is a result 
of a wide margin operation outside the “pseudocapsule” 
area (containing squeezed and altered normal tissue 
surrounding the tumour altogether with tumour cells). 
The most important elements of the surgical technique 
(Tab. 3) include:
 — removal of the tumour in one block with the sur-
rounding normal tissue (en bloc resection) and the 
surroundings diagnostic biopsy;
 — removal of the tumour covered on each side with 
a layer of healthy tissue. The tumour should not be 
visible to the operating team macroscopically;
 — performing a long-cut operation (“from joint to 
joint”), which allows closer inspection of tendon 
trailers to the muscular bone of the operated limb.
Soft tissue localisation in the retroperitoneal space is 
a particular therapeutic challenge. The most desirable is 
resection (in one block with adduced/adjoining organs) 
[8, 9], which is possible in 50–85% of patients. The 
completeness of excision impedes the anatomy, the lack 
of real muscle compartments, asymptomatic tumour 
growth larger, and infiltration of vital organs. 
The principle of surgical treatment of STS is radical 
resection of the tumour. Recommendations for reach-
ing a centimetre-wide margin of tumour-free tissue in 
practice are difficult to implement. The margin obtained 
is narrow in the case of anatomically resistant structures 
(e.g. muscle fascia, periosteum, and nerves) and may be 
extensive in other soft tissues (e.g. muscles, especially 
in the longitudinal axis of the limb). As a rule, the STS 
resection radicalism is evaluated by R classification 
(R0 — microscopically radical resection, R1 — micro-
scopically non-radical resection, R2 — macroscopi-
cally non-radical resection). R0 is a well planned and 
performed resection of STS with a microscopically 
unchanged healthy tissue margin, which is a prerequi-
site for obtaining histopathological diagnosis by biopsy. 
R1 implies that in the postoperative pathological exami-
nation a microscopic tumour infiltration was found in 
the surgical cutting line. Category R1 also includes all 
accidental resections (i.e. without prior preoperative 
histological verification, regardless of the circumstances 
and the description of the operation). In the case of 
R1 resection, a second resection can be considered if 
appropriate margins can be obtained without signifi-
cant complications. Leaving the macroscopic lesions of 
Table 3. Basic and detailed principles used in surgical treatment of sarcoma of soft tissues
I. General rules: II. Detailed rules:
 — freedom of decision as to the scope of operations (for 
conserving surgery, patient consent for a possible amputation)
 — tumour excision in one block
 — skin incision containing site after prior surgery (biopsy)
 — keeping the margin of healthy tissue in all directions
 — excision of the muscles of the tumour whole or with a wide 
margin
 — excision of vessels and nerves covered by tumour infiltration 
at a distance of 3–5 cm from the tumour
Note: in the long axis the radical is usually retained; pay 
attention to the appropriate tissue margin in the transverse 
dimension of the limb (especially with natural barriers such as 
vascular adventitia, periosteum, perineurium, muscle fascia)
 — careful protection of tumour ulceration or damaged 
fragments of sarcoma
 — avoiding unnecessary tumour pressure
 — fast and accurate ligation of blood vessels, the use of vascular 
clips
 — manipulation in macroscopically healthy tissues  
(i.e. "cut sarcoma without seeing it")
 — the most important task of the operation is radical excision 
sarcoma, then you should consider the issue of possible 
reconstruction
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Table 4. General scheme of the strategy of in the treatment of soft tissue sarcoma
Stage Surgery Radiotherapy* Chemotherapy*
I + – –
II + + –
III + + +/?
IV ?/+ ? +
*According to the protocols of relevant clinical trials, with the exception of adjuvant perioperative radiotherapy or palliative chemotherapy 
? — individualisation of management
sarcoma during surgery signifies resection of surgical 
margin R2. In the case of R2 resection, if possible, care-
fully planned reoperation should be proposed, if possible 
associated with adjuvant preoperative treatment. 
Amputation in STS patients is now rarely performed 
(< 10% of patients) because in most cases proper 
sparing operations in combination with RTH provide 
similar local tumour control and overall survival. The 
basic condition for limb preservation is the possibility 
of radical surgery with a low risk of local recurrence 
while maintaining good performance and functionality 
of the limb. 
It should be emphasised that there is no scientific 
evidence to support the use of non-radical macroscopic 
surgical treatment (R2) in combination, provided that 
the combination of non-radical excision with other 
methods (RTH and/or CTH) will help cure the patient. 
Patients with STS rarely have isolated metastases 
in regional lymph nodes; this concerns mainly rhabdo-
myosarcoma and epithelioid sarcoma, and clear cell and 
synovial sarcoma. The presence of lymph node metastasis 
is significantly adversely prognostic — these cases should 
be treated as spread of the disease, and the treatment 
plan should include preoperative CTH and RTH. 
Surgical treatment of isolated lung metastases (re-
section saving pulmonary parenchyma) is the procedure 
of choice in the case of countable changes and possible 
resectable. The primary prognostic factor is radical 
resection of the metastatic disease during surgery. Me-
tastasectomy as an isolated treatment modality is highly 
recommended in patients with oligometastatic disease 
and metastatic lung disease that has been reported me-
tachronically over a longer period of time after primary 
treatment; disease-free interval should be over a year 
[III, A] [1, 3, 10].
It is recommended that the combination treatment 
be individualised in patients with STS with the following 
general guidelines (Tab. 4) [1, 3, 11] [II, A]:
 — exclusive radical surgical treatment justified in 
patients with stage IA (low-grade malignancy, su-
perficial position, size ≤ 5 cm) according to TNM;
 — radical surgical and adjuvant RTH pre- or post-
operative (justifying STS treatment in specialised 
centres with RTH) — STS in other stages of TNM 
(IB, IIA, IIB, IIC);
 — prospective clinical trials (optimally with preopera-
tive CTH and RTH) or individualised multimodality 
therapy — advanced STS with presence of risk fac-
tors for spread but without metastases (high grade of 
G3–G4 histology and > 10 cm — M0), but treatment 
should not be initiated outside the reference centres;
 — analogous treatment to primary treatment — all 
recurrences (local recurrence) of STS;
 — initiation of treatment with CTH, and in case of 
response and with countable metastases (resectable) 
radicalisation of the procedure (radical excision 
of primary change in combination with CTH and 
local treatment of metastases) — STS in stage IV 
(N1, M1).
Therapeutic regimen is shown in Figure 2. After 
proper diagnosis, most patients after radical surgery 
(R0 resection) require supplementary RTH several 
weeks of rehabilitation and continuing check-ups at the 
treatment centre for at least five years.
Adjuvant radiotherapy
Randomised clinical trials have shown that the use 
of combination therapy in the form of a broad STS 
resection and adjuvant RTH allows for local tumour 
control in 85–90% of cases, and patient survival is 
no different from that achieved with amputation 
[II, B] [12]. There is no agreement on the sequence 
of irradiation and surgical treatment, and the final 
RTH (tele- or brachytherapy) method has not been 
established [13, 14]. The results of a phase III clini-
cal trial conducted by the Canadian National Cancer 
Institute (NCI-C) did not show a clear advantage of 
preoperative over postoperative RTH. The benefits of 
preoperative RTH (e.g. limited area, lower dose, less 
risk of implantation of STS cells in the surgical wound, 
easier surgical intervention, lower rate of late com-
plications) limit complications in wound healing [15]. 
The recommended dose for postoperative RTH is 
60–66 Gy, and the treatment lasts 7–8 weeks. In 
conventional fractionated preoperative radiotherapy 
(1.8–2 Gy per day) the total dose is 50–50.4 Gy. The 
surgery is performed 4–8 weeks after the end of irra-
diation. The results of individual studies also indicate 
the possibility of using hypofractionated preoperative 
radiotherapy [16].
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Figure 2. Scheme of treatment in localised resectable soft-tissue sarcomas
The indications for adjuvant RTH (conformal 
technique) in STS patients differ in following clinical 
situations [II, B]:
 — after the resection of the primary lesion:
•	 high malignancy, size greater than 5 cm,
•	 microscopic surgical margin below 1 mm (espe-
cially if suspected of spreading intraoperative by 
tumour damage during operation),
•	 all small-cell STS in combination with CTH,
•	 all STS located within the trunk and head and 
neck or after a previous operation (early — scars 
and operating are after a previous operation 
performed with the inappropriate margin; or 
late — resection of the recurrence confirmed mi-
croscopically).
Adjuvant (preoperative or postoperative) 
chemotherapy
Adjuvant CTH in adult patients with STS (ex-
cept for small-cell STS and rhabdomyosarcoma) 
without disease spread is not a standard treatment. 
A meta-analysis of 14 clinical trials and 1568 STS 
patients undergoing postoperative CTH using doxo-
rubicin showed improvement in disease-free survival 
by 10% (significant difference) and overall survival by 
approximately 6% (non-significant difference) [17]. 
There is no clear evidence to improve the prognosis 
with the use of postoperative or postoperative CTH 
[18], but in individual STS with a diameter greater 
than 5 cm and a high degree of histological malignancy 
(G3), it is possible to decide on adjuvant treatment 
(especially in chemo-sensitive histological subtypes, 
e.g. synovial sarcoma [II, C] or CTH combination 
with hyperthermia [I, C]. In a recently published 
phase III randomised trial, it was demonstrated that 
in preoperative treatment of patients with high-risk 
STS located within the limb or trunk, chemotherapy 
adapted to the histological type of sarcoma should 
not be used because patients in the control group re-
ceiving three cycles of epirubicin and ifosfamide had 
a lower risk of recurrence or death, and the study was 
therefore discontinued. Consequently, patients with 
may be treated with a preoperative chemotherapy 
based on anthracycline with ifosfamide after careful 
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multi-specialist evaluation of the potential benefit and 
the risk of adverse events [19]. 
Regional hyperthermia in combination with comple-
mentary CTH has been shown to improve local control 
and relapse-free survival (possible treatment [20]) in one 
randomised clinical trial (STS G2–3, sub-fascial, > 5 cm). 
In the case of locally advanced limbic STS, one of the 
options is the preoperative use of isolated limb perfusion 
with cytostatics in hyperthermia [III, A] [21].
Treatment of metastatic disease
In the case of spread of the disease we can identify 
patients with:
 — primarily surgical metastases limited to one or-
gan (mainly lung), for which initial CTH, surgical 
metastatic excision, and subsequent CTH should 
be considered;
 — more advanced and unresectable metastases for 
which treatment should be individualised (CTH, 
RTH, symptomatic treatment).
The standard first-line CTH is anthracyclines (doxo-
rubicin and epirubicin) [I, A] [22, 23] ± olaratumab 
(anti-PDGFR-alpha antibody) [I, B]. Ifosfamide, dac-
arbazine, gemcitabine, docetaxel, trabectedin, eribulin, 
and pazopanib are also active in the second line of 
treatment [24–26]. The results of clinical studies did not 
show a significant advantage of multidrug CTH over 
monotherapy, and administration of regimens (e.g. dox-
orubicin and dacarbazine) may be considered in selected 
histological types of high chemosensitivity and in cases 
in which the response to treatment depends on the pos-
sibility of surgical treatment of metastases. Some drugs 
may be used in specific STS types [II, B] (e.g. taxanes 
— angiosarcoma; gemcitabine ± docetaxel — leiomyo-
sarcoma; trabectedin — liposarcoma, especially myxoid 
liposarcoma or leiomyosarcoma [I, A] [25]; ifosfamide 
— synovial sarcoma; imatinib — dermatofibrosarcoma 
protuberans [27]; sunitinib — alveolar soft part sarcoma; 
mTOR-inhibitors PEC-oma/lymphangioleiomyomato-
sis; crizotinib — inflammatory myofibroblastic tumour 
with the presence of ALK rearrangement. The efficacy of 
trabectedin in the treatment of L-sarcoma after failure of 
at least one systemic treatment line has been confirmed 
in three randomised phase III trials [25, 28, 29] [I, A], 
and in phase II trials confirmed clinical benefit from 
maintenance therapy for progression of disease in 
patients who had disease control after six cycles of 
trabectedin [30]. Another drug for use in patients with 
advanced STS (other than liposarcoma) following failure 
of prior CTH is pazopanib — results of a randomised 
trial have shown improvement in progression-free 
survival of three months [26]. The promising results of 
randomised phase III and II controlled trials indicate 
the activity of eribulin in advanced liposarcoma [I, B] 
[31] and olaratumab in combination with doxorubicin 
in the first-line treatment of advanced STS [IB] [32]. 
Eribulin compared with dacarbazine in patients with 
advanced liposarcoma and leiomyosarcoma gave im-
provement in overall survival compared to dacarbazine 
(the median of 13.5 vs. 11.5 months). The benefit of 
therapy was seen primarily in liposarcoma patients. In 
the olaratumab study, the median overall survival was 
26.5 months (95% CI 20.9–31.7) for combination with 
doxorubicin (66 patients) and 14.7 months (95% CI 
9.2–17.1) for doxorubicin monotherapy (67 patients) 
(HR 0.46, 95% CI 0.3–0.71, p = 0003), but these results 
need confirmation in the ongoing phase III study. In the 
United States, pre-registration of the EZH2 inhibitor 
tazemetostat was based on the preliminary results of 
a phase II study in adult patients with INI1-negative 
epithelioid sarcoma [II, C] [33].
Progress in systemic treatment of STS is related to 
the use of molecularly-targeted drugs that target specific 
intracellular metabolic pathways essential for etiopatho-
genesis and tumour progression. Some of these drugs 
have been registered in certain STS (Tab. 5).
Table 5. Molecular-targeted drugs that have registered indications in soft tissue sarcoma
Histological type of tumour    Drug           Molecular target
GIST Imatinib KIT, PDGFRA
GIST Sunitinib KIT, PDGFRA, VEGFR
GIST Regorafenib KIT, PDGFRA, VEGFR
DFSP Imatinib PDGFRB
Liposarcoma
Leiomyosarcoma
Trabectedin ? NER/minor groove of the DNA helix
The different histological types, except liposarcoma, mainly after 
failure of prior therapy
Pazopanib VEGFR, PDGFR
The different histological types in first-line therapy in combination  
with doxorubicin
Olaratumab PDGFRA
GIST — gastrointestinal stromal tumour; DFSP — dermatofibrosarcoma protuberans
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The five-year survival rate is 35–75%; the worst 
results are achieved in surgical departments with no ex-
perience in STS treatment, intermediate results (about 
60%) are published in multicentre clinical trial results, 
and the best come from multi-modality (unit) oncologi-
cal centres using the full range of resources.
Special clinical situations
Soft tissue sarcomas of the breast
They account for about 1% of all recorded breast 
malignancies, including sporadic and previously irradi-
ated tumours [34]. The most common types of histol-
ogy are: malignant phyllodes tumour, angiosarcoma, 
and fibrosarcoma with varying degrees of histologic 
malignancy [35]. Angiosarcoma (usually with a high 
degree of malignancy) has a strong tendency towards 
local recurrence and is characterised by a worse clini-
cal course, requiring a priori aggressive treatment with 
radiotherapy (chemotherapy) (high sensitivity to pacli-
taxel). The surgical treatment of choice should be simple 
amputation of the breast (especially in angiosarcoma) 
or radical resection without axillary lymphadenectomy; 
neoadjuvant radiotherapy (or possibly chemotherapy) 
is recommended according to the treatment regimen, 
as with other STS [1, 3].
Uterine sarcomas
The European Society for Medical Oncology distin-
guishes the following types of uterine sarcoma: leiomyo-
sarcomas (LMS), endothelial stromal sarcomas (ESS), 
undifferentiated endometrial sarcomas, and pure heter-
ologous sarcomas (most commonly rhabdomyosarcoma, 
chondrosarcoma) [3]. The clinical classification of TNM 
and FIGO (International Federation of Gynaecologists 
and Obstetricians) is presented in Table 6. The prognosis 
for low-grade malignant sarcoma (ESS) is good — the 
five-year survival is 80–100% even though 20–40% of 
patients have local recurrence of the disease after treat-
ment [36, 37]. For patients with diagnosed LMS and 
high grade malignant sarcoma, prognosis is poor [34, 35] 
— three years of relapse-free survival is seen in only 
about 30% and is worse for postmenopausal women. In 
the case of distant recurrence, palliative chemotherapy 
is the primary option — the median overall survival 
in this group of patients is about 13 months. The only 
option that gives a chance for a cure in the case of late 
relapse is metastasectomy (mainly from the lungs). 
The standard local treatment for all these cancers is 
removal of the uterus from abdominal access [II, A] 
[36, 37]. The importance of bilateral adnexectomy 
is not fully understood, although in stromal uterine 
sarcoma it is generally recommended because of the 
hormonal sensitivity of these tumours [III, A] [36, 37]. 
Ovarian retreatment in women under 35 years of age is 
recommended for tumours smaller than 3 cm, but it is 
important to discuss the potential recurrence risk with 
the patient. In cases of LMS and non-differentiated 
sarcomas, both bilateral removal of adnexa (especially 
in premenopausal women) and pelvic lymphadenectomy 
did not show improvement in treatment outcome in the 
absence of macroscopic involvement of these tissues. In 
patients whose LMS was diagnosed postoperatively (e.g. 
after hysterectomy due to uterine fibroids), and in whom 
the procedure was microscopically radical (reoperation 
is not recommended in this case), imaging studies should 
be performed to exclude distant metastases because it 
is reported that up to 10% of patients with LMS have 
metastatic lesions in the lungs at diagnosis. In the case 
of locally advanced unresectable tumours, palliative 
radiotherapy should be considered [36, 37] [III, B]. 
Although there are reports of retrospective studies on 
the possible reduction of local recurrence using adjuvant 
radiotherapy in patients with uterine LMS, the impact on 
local recurrence and overall survival were not confirmed 
in the only randomised clinical trial [38]. Thus, comple-
mentary postoperative radiotherapy in this diagnosis is 
only a treatment option [II, C], and the decision to use 
postoperative radiotherapy may only affect a small pro-
portion of patients with high risk of local recurrence, and 
it should be followed by careful multidisciplinary analysis 
of the case and an interview with the patient [36, 37]. In 
the case of ESS there are reports suggesting improved 
survival in patients who have received postoperative 
hormone therapy (progesterone analogues — most com-
monly megestrol acetate or medroxyprogesterone), so 
it is recommended for patients in grades II–IV [III, B] 
[36, 37]. As in all adult soft tissue sarcomas, the role 
of adjuvant chemotherapy in LMS uterus is not fully 
established [III, C]. Progesterone analogues, aromatase 
inhibitors, or LH-RH analogues (for premenopausal 
women) can be used as treatment for advanced uterine 
sarcoma. Oestrogen-based therapies and tamoxifen are 
contraindicated [II, B]. Treatment of advanced/meta-
static leiomyosarcoma and non-differentiated sarcoma 
is similar to systemic treatment of other soft tissue 
sarcomas [1, 3, 36, 37].
Fibromatosis (aggressive fibromatosis, desmoid-type  
fibromatosis)
Fibromatosis is a disease with the clinical course of 
locally malignant STS, with no metastatic disease, char-
acterised by local infiltration and the ability of local re-
currence. The principle of the therapy is multi-specialist 
assessment and individualisation of treatment. In recent 
years the most common treatment is conservative treat-
ment and active observation [III, B]. Results of active 
observation (wait-and-see) indicate that only about 20% 
of patients progress, and some patients experience not 
only stabilisation but also spontaneous regression after 
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Table 6. Clinical classification of uterine sarcomas according to TNM (tumour/node/metastasis) and FIGO (Federation of 
Gynaecology and Obstetrics)
Primary tumour (T)
TNM FIGO Definition
Leiomyosarcoma and endometrial stromal sarcoma
TX The tumour cannot be assessed
T0 No evidence of primary tumour
T1 I Tumour limited to uterus
T1a IA Tumour of the largest size ≤ 5 cm
T1b IB Tumour in the largest dimension > 5 cm
T2 II The tumour infiltrates tissue located outside the uterus but within the pelvis
T2a IIA The tumour infiltrates the appendix
T2b IIB The tumour infiltrates the remaining pelvic tissues
T3 III The tumour infiltrates the abdominal tissue
T3a IIIA One place
T3b IIIB More places
T4 IVA The tumour invades the bladder or rectum
Adenosarcoma
TX The tumour cannot be assessed
T0 No evidence of primary tumour
T1 I Tumour limited to uterus
T1a IA Tumour limited to the endometrium/endocervix
T1b IB The tumour infiltrates less than half the thickness of the myometrium
T1c IC The tumour infiltrates more than half the thickness of the myometrium
T2 II The tumour infiltrates tissue located outside the uterus but within the pelvis
T2a IIA The tumour infiltrates the adnexa
T2b IIB The tumour infiltrates the remaining pelvic tissues
T3 III The tumour infiltrates the abdominal tissue
T3a IIIA One place
T3b IIIB More places
T4 IVA The tumour invades the bladder or rectum
Regional lymph nodes (N)
TNM FIGO Definition
Leiomyosarcoma and endometrial stromal sarcoma 
NX Regional lymph nodes cannot be assessed
N0 No lymph node metastases
N1 IIIC Lymph node metastases
Adenosarcoma
NX Regional lymph nodes cannot be assessed
N0 No lymph node metastases
N1 IIIC Lymph node metastases
Metastases (M)
TNM FIGO Definition
Leiomyosarcoma and endometrial stromal sarcoma 
M0 No metastases
M1 Metastasis (excluding adnexa, pelvic and abdominal cavity)
Adenosarcoma
M0 No metastases
M1 Metastasis (excluding adnexa, pelvic and abdominal cavity)
Æ
192
OncOlOgy in clinical practice 2017, Vol. 13, No. 5
Staging of uterine sarcomas
I T1 N0 M0
IA T1a N0 M0
IB T1b N0 M0
IC T1c N0 M0
II T2 N0 M0
IIIA T3a N0 M0
IIIB T3b N0 M0
IVA T4 Any N M0
IVB Any T Any N M1
Table 6 cont. Clinical classification of uterine sarcomas according to TNM (tumour/node/metastasis) and FIGO (Federation 
of Gynaecology and Obstetrics)
about one year of follow-up [39, 40]. In progressive, 
symptomatic cases, surgery is performed within healthy 
tissues (sometimes in combination with postoperative 
radiotherapy) [1, 40] but remembering the principle 
that treatment should not lead to significant functional 
impairments. In the case of extensive lesions, or if the 
operation would involve severe disability, the use of 
radiotherapy alone is considered. The recommended 
dose of irradiation is 56 Gy in fractions of 2 Gy. The 
margin with which the lesion is irradiated is at least 
5 cm. The use of radiotherapy should be particularly 
limited at an early age and in the abdominal location 
(especially in coexistence with familial adenomatous 
polyposis) [40]. In non-operative cases, in the case of 
very extensive tumours, when surgery or radiotherapy is 
associated with severe disability, progressive treatment 
despite irradiation is followed by pharmacological treat-
ment — most commonly starting with oral nonsteroidal 
anti-inflammatory drugs: indomethacin 100 mg/day or 
sulindac 300 mg/day or meloxicam 15 mg/day (these 
drugs may also be used during active observation) [III, 
B]. Other non-cytotoxic drugs are hormonal medica-
tions: anti-oestrogens — tamoxifen at doses of 20 to 
120 mg/day or MPA (medroxyprogesterone acetate) 
500 mg/day [1, 40]. In the absence of response to 
the above-mentioned treatment, classical cytotoxic 
chemotherapy is generally used with anthracyclines or 
vinblastine with methotrexate. There are also reports of 
the activity of multiple kinase inhibitors.
Rehabilitation
Rehabilitation should be started before surgery and 
implemented as early as possible after surgery and dur-
ing follow-up, in some cases even for several years (due 
to late complications of RTH, e.g. contracture in joints). 
Within the framework of rehabilitation it is necessary 
to cooperate with specialists in the field of physical 
therapy, prosthetics, social and professional adaptation, 
and psychologists and psychiatrists.
Follow-up after treatment
The purpose of follow-up of patients after treatment 
of STS is early detection of possible recurrence of the 
disease, given the possibility of extending survival with 
less advanced metastatic disease or local recurrence 
(proposed standard recommendations of observation 
after treatment of STS — Tab. 7) [1, 3, 41].
Most recurrences (about 80%) occur within three 
years of primary tumour treatment. STS relapse depends 
largely on the location of the primary tumour. In patients 
with STS with limb location the primary recurrences 
(metastases) are usually to the lungs, while in patients 
undergoing proper treatment local recurrences develop 
less frequently. Lymph node metastases may occur in 
some types of STS of the extremities and trunk (e.g. 
rhabdomyosarcoma, epithelioid sarcoma, clear cell 
sarcoma, or synovial sarcoma, and metastases in the 
abdominal organs are observed in the myxoid liposar-
coma). In STS of retroperitoneal space or viscera, most 
commonly are observed local recurrences, and secondly 
liver metastases. 
The results indicate that the effects of the treatment 
of adult patients with metastases in the lungs is improved 
in the case of a smaller number of metastatic lesions, in-
dicating directly the importance of early detection during 
follow-up. Analysis of the importance of regular follow-up 
examinations after STS treatment show that chest X-ray 
allows more than 60% of lung metastases to be detected 
before the onset of clinical symptoms — chest X-ray is 
sufficient in routine chest control studies and there is no 
need for chest CT. Detection or suspicion of a nodule 
in the chest X-ray is an indication to perform a CT to 
confirm the metastasis and to evaluate the number and 
location of lung nodules, pleural imaging, and mediasti-
nal, lumbar, and mediastinal lymph nodes. Periodic chest 
CT examination should be performed only in patients 
with STS with a very high risk of spread of the disease and 
metastases after resection. After five years of follow-up, 
chest X-rays should be performed at 12-month intervals. 
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Table 7. Scheme of follow-up in patients with soft tissue sarcomas
Tumour stage Type of follow-up The frequency of 
follow-up
After radical treatment of 
sarcoma in stages IA–IB (low 
histological grade G1)
Physical examination every 3–6 months for the first 2–3 years, then once 
a year. Chest X-ray every 6–12 months, CT only in case of suspicion of 
lesions in RTG. Consider local evaluation after resection 6 months after 
surgery with imaging (MR, CT, or USG); regular checks every 6 months 
(for the first 2–3 years, then once a year) with contrast-enhanced CT 
only for retroperitoneal and intraperitoneal space sarcoma, in other 
cases imaging only with clinical suspicion of recurrence. The need for 
education of the patient in the field of self-control
Every 3–6 months during 
the first 2–3 years, 
then every 12 months 
(> 10 years, only in 
cases undergoing 
perioperative RTH)
After radical treatment 
of sarcoma in stages II–III 
(with higher histological 
grade G2/G3 or after lymph 
node metastasis)
Symptoms and physical examination, especially of the scar after sarcoma 
resection and regional lymph nodes. RTG or CT of the chest. Initial site 
evaluation 3–6 months after surgery (MR, CT, or USG) may be used to 
control the site of surgery. Ultrasonography may be used; other tests 
should not be performed more than once a year. Regular check-ups 
every 6 months (for the first 2–3 years, then once a year) with CT and 
contrast pelvic examinations only in retroperitoneal and intraperitoneal 
space sarcoma, due to the difficulty in assessing the location of the 
tumour. The need to educate the patient towards self-control
Every 3–4 months for the 
first 2–3 years, then every 
6 months to 5 years after 
radical treatment, then 
once a year
After treatment of distant 
metastases (grade IV)
Evaluation in imaging studies based on the location of measurable 
metastatic foci
Individual follow-up 
schedule for every patient
Follow-up to detect local recurrences primarily 
should include a careful examination, with the possible 
addition of scar ultrasound (USG) in the case of lesions 
easily accessible on the limbs or trunk. The patient 
should also be advised on the possible recurrence of 
symptoms, as the self-control of scar tissue after primary 
excision, made by the patient, often leads to finding of 
relapse of the disease outside the control visit schedule. 
Some experts recommend that for patients with 
high-grade STS located in the limb, the original loca-
tion of the tumour should be assessed with ultrasound 
or MRI (routine use of these tests is not justified on 
the basis of analyses of efficacy against costs). In the 
case of STS originally located in the retroperitoneal, 
intraperitoneal, or inguinal area, imaging methods (CT 
or MR) are effective. Local recurrences in the retro-
peritoneal or intraperitoneal space are more frequent 
than in the limb or abdominal and thoracic areas (these 
locations are inaccessible in the physical examination). 
Less aggressive control regimens are warranted, espe-
cially in the case of second retroperitoneal recurrence 
(no evidence of survival improvement in the event of 
early relapse). 
In experienced oncology centres, routine check-ups 
are performed every 3–4 months for the first 2–3 years 
after treatment and then every six months for the next 
two years, and later once a year. The risk of recurrence 
of the disease depends on the degree of histological 
malignancy and the size of the STS, if the primary 
treatment was radical, and the time from the initial 
treatment. It is known that in low-grade STS and particle 
size smaller than 5 cm the risk of relapse after radical 
treatment is very low. In the case of easy accessibility 
of postoperative scar, when it is possible to assess by 
physical examination, there is no need to perform any 
additional imaging studies, and it should be consid-
ered only to perform chest X-ray in two planes every 
6–12 months for the first three years, and then a check 
every year. On the other hand, in cases of high-grade 
malignancy, the risk of metastases to the lungs and local 
recurrence is significant, it is necessary to perform cyclic 
chest X-ray, and — in addition to careful examination of 
the subject — it may be justified to direct the patient to 
the imaging examination of the area after the primary 
tumour. None of the laboratory tests used thus far lead 
to effective detection of STS recurrence. In the case 
of locations that are difficult to access in the physical 
examination (retroperitoneal and intraperitoneal site), 
periodic assessment for disease recurrence should be 
made by means of imaging studies (choice — CT with 
contrast). The value of positron emission tomography 
(PET) is not yet established. It is also important to in-
form the patient that even 10 years after primary STS 
treatment, there may be late cancer recurrence or the 
development of tumours induced by radiotherapy during 
combination therapy.
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Gastrointestinal stromal tumours
GISTs are a separate group of the most common 
mesenchymal tumours of the gastrointestinal tract, prob-
ably derived from precursors of Cajal “pacemaker” cells 
(responsible for peristaltic intestinal movement). The 
initiating factor for malignancy is an activating muta-
tion in the genes encoding membrane receptor KIT or 
PDGFRA, overexpression of which is highly specific for 
GIST, and overexpression of membrane receptor KIT 
can subsequently be detected by immunohistochemistry 
(IHC) expression of CD117 in histological sections, 
which is the main criterion in its microscopic diagnosis 
and indications for the treatment with small molecule 
tyrosine kinase inhibitors [1, 42, 43]. Clinically, GIST 
represents a broad spectrum of lesions — from small, 
benign tumours found accidentally during endoscopic or 
surgical procedures, to very aggressive tumours leading 
to massive metastases. These cancers, thanks to advanc-
es in the diagnosis of pathological molecules, are widely 
recognised only after several years. The basic and valid 
principle should be the treatment of GIST inoperative 
and/or metastatic GISTs within multidisciplinary teams 
experienced in the treatment of STS. Treatment should 
be limited to a few specialised centres in Poland, which 
justifies a small number of patients eligible for tyrosine 
kinase inhibitors therapy (about 200 per year).
Epidemiology
Epidemiological findings on GIST of the gastro-
intestinal tract are rarely published. A retrospective 
population-based study in Sweden showed that the inci-
dence of GIST (including low-risk and aggressive forms) 
is 15–16 cases/year/million — in Poland this would cor-
respond to more than 600 new cases annually. In the 
United States the number of metastatic/non-operative 
GISTs is estimated at over 1000 new cases per year 
(3–4 cases per 1 million inhabitants); this would mean 
that 150–190 new metastatic GIST cases can be expected 
in Poland. The GIST Registry Report (gist@coi.waw.pl; 
http://gist.coi.pl) indicates that these are now the most 
commonly diagnosed malignant mesenchymal tumours 
of the gastrointestinal tract.
The majority of patients (75%) at the time of diag-
nosis are over 50 years of age (median: 55–65 years), 
but GIST can occur at any age. 
Approximately 90% of GISTs have primary location 
in the gastrointestinal tract, much more rarely in the 
retroperitoneal space, or they cannot be established due 
to multifocal intraperitoneal spread (< 10%). Popula-
tion studies show that GISTs are most common in the 
stomach (40–70%), followed by the small intestine 
(20–50%), and less often in the large intestine (about 
5%) or oesophagus (less than 5%).
Diagnostics
Symptoms and physical examination
GIST clinical symptoms are non-specific and include 
abdominal pain, obstruction or chronic gastrointestinal 
bleeding, and perceptible abdominal tumours (some-
times acute “abdominal symptoms”). Minor lesions 
remain asymptomatic and can be detected acciden-
tally. Some (about 40%) GIST patients are operated 
in gynaecological departments, with initial diagnosis of 
ovarian cancer. 
GIST relapses after primary surgery are mainly in 
the abdominal cavity. In more than half of the cases 
there are metastases in the liver (isolated or coexisting 
with intraperitoneal spread). Isolated intraperitoneal 
spread is found in about 30–40% of patients. Isolated 
local recurrences are rare.
Imaging studies
CT scan of the abdomen with intravenous and oral 
contrast is the preferred imaging modality used in GIST 
for staging and planning of the surgical procedures, 
including laparotomy and biopsy (R2). In the case of 
GIST located in the rectum, diagnostic MR may be used 
alternatively, and in case of GIST suspicion, endoscopic 
ultrasonography is helpful.
Pathological assessment
In the case of primary GIST suspicion, with appropri-
ate technical conditions, a needle biopsy under endo-
scopic ultrasound may be performed — a core-needle 
biopsy or an open biopsy by laparotomy (cut or incision); 
some of the fresh material should be freeze-free (about 
–80°C) for possible molecular testing. In the case of mi-
nor lesions (≤ 2 cm) of the upper gastrointestinal tract, 
endoscopic examination may be the only procedure, and 
any possible removal of the lesion may be reserved for 
cases of enlargement during observation [IV, C].
GISTs are characterised by microscopic epithelioid 
or spindle epithelial cells and mixed (exceptionally: 
pleomorphic). All mutations in the KIT or PDGFRA 
genes are receptor activating, and in most cases GIST 
expresses the CD117 antigen (a protein epitope pro-
duced by the KIT gene) and/or DOG1, which can be 
detected by immunohistochemistry. In a few cases (less 
than 5%) CD117 expression is not observed in the pres-
ence of mutations in the KIT or PDGFRA genes. The 
term “benign” GIST is not used. In CD117-negative 
tumours, the presence of mutations in the KIT and 
PDGFRA genes is required along with re-consultation at 
a pathology facility experienced in GIST diagnosis. The 
test material may be tumour tissue from a paraffin block 
or (better) frozen tissue.
Mutations in the KIT and PDGFRA genes that en-
code membrane receptors with tyrosine kinase activity 
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Figure 3. Treatment algorithm in gastrointestinal stromal tumours (GIST)
are mutually exclusive (i.e. not present in both genes 
simultaneously) and activated (i.e. receptors become 
metabolically active without the need to bind to ligand). 
The GIST mutations are most commonly observed in 
KIT proto-oncogene — most (about 70%) occur in exon 
11, rarely in exon 9 (6–8%), and occasionally in exon 
13 and 17. In many GISTs where there is no KIT muta-
tion there are mutations in the PDGFRA gene (mainly 
exon 18 and, less often, exon 11). The presence of the 
mutated KIT or PDGFRA gene in GIST is important in 
predicting the response to imatinib — in each case of 
GIST diagnosis and after initiation of treatment, it is 
recommended that the material (may be paraffin blocks) 
is sent for molecular assay [IV, B].
Treatment
The principles of diagnostic and therapeutic proce-
dures in GIST are presented in Figure 3. It is recom-
mended that patients are treated by multidisciplinary 
teams experienced in GIST therapy, and that new cases 
of this type are included in prospective clinical trials.
Primary surgical treatment
The most effective method of treatment for GIST 
is radical surgical treatment with the intention of cure 
(35–65% of five-year survival without relapse), which 
consists of open resection of the stomach, small intes-
tine, intestine fat, or intraperitoneal/retroperitoneal 
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injection within the limits of macroscopically healthy 
tissue (Tab. 8).
In the case of the gastric GIST, most often local ex-
cision of the tumour with a fragment of the wall of the 
stomach (wedge resection) is performed, less frequently 
partial or total resection (extent of gastric resection is 
not relevant for the risk of recurrence of cancer), and 
subsequent reoperations of recurrent GIST do not lead 
to cure. In other sites, segmental resection of the small 
intestine or hemicolectomy are performed. Unlike in 
carcinomas of the digestive system there is no need to re-
move the loco-regional lymphatic system because lymph 
node metastases occur sporadically in GIST (< 3% of 
patients). In the case of R1 resection (microscopically 
non-radical resection), re-operation may be considered 
as long as it is possible to determine the location of 
the primary tumour and the surgery is not connected 
with serious consequences for the functioning of the 
alimentary tract (in which case, only observation after 
surgery is recommended). It is not recommended that 
laparoscopic R1 resection in primary GIST of larger 
sizes be performed. Surgical techniques with lower in-
vasiveness (e.g. laparoscopic resections and endoscopic 
techniques) will probably play an increasingly important 
role in the removal of small gastric GIST. The method 
of local excision through the anus in the future may be 
used in the removal of small GIST with low risk of ag-
gressiveness and rectal location. During the operation 
it is particularly important to avoid damage or rupture 
of the tumour because it is considered a negative prog-
nostic factor.
In patients with locally advanced GIST (borderline 
operability) extensive multiorgan resections should 
be avoided (e.g. abdominal-pectoral amputation or 
pancreatoduodenectomy), and reoperations of relapse 
are particularly inadvisable (GIST diagnosis is already 
known after the first surgery). In these situations, treat-
ment with imatinib should be considered before surgery 
(daily dose 400 mg) with closely controlled CT per-
formed every two months, with the possibility of surgical 
procedures in cases of maximum response to imatinib, 
usually after 6–12 months of therapy [II, A] [44].
Assessment of the risk of relapse and the principles 
of observation after primary therapy
For each patient after primary GIST surgery and 
receiving a definitive histopathological result, the risk of 
recurrence should be assessed according to the National 
Comprehensive Cancer Network (NCCN-AFIP-AJCC) 
classification, which is the basis for the classification of 
staging AJCC 2010 (Tab. 9) [45]. The most important 
risk factors for recurrence after primary excision are 
the value of the mitotic index, the size and location of 
the tumour, and the state of the surgical margins (es-
Table 8. Principles of primary surgical treatment of 
gastrointestinal stromal tumours (GIST)
Resection of the tumour within the healthy tissues (the 
margin of 1–2 cm; preferred organ-sparing operations, wedge 
excisions )
Avoiding intraoperative tumour rupture
Usually lymphadenectomy is not necessary
The role of laparoscopy is uncertain (contraindicated for 
larger tumours)
Precise evaluation for metastatic disease (especially 
exploration of the peritoneal recesses)
Consideration of the initial treatment with imatinib instead of 
mutilating surgery in locally advanced cases
Securing tissue (freezing) for molecular tests
Table 9. TNM staging of gastrointestinal stromal tumours (GIST)
GIST of the stomach/omentum Intestine GIST  
(+ mesentery, oesophagus, intraperitoneal)
Stage       T   N      M      IM Stage       T  N  M      IM
IA T1 or T2 N0 M0 Low I T1 or T2 N0 M0 Low
IB T3 N0 M0 Low II T3 N0 M0 Low
II
T1 N0 M0 High
IIIA
T1 N0 M0 High
T2 N0 M0 High T4 N0 M0 Low
T4 N0 M0 Low
IIIB
T2 N0 M0 High
IIIA T3 N0 M0 High T3 N0 M0 High
IIIB T4 N0 M0 High T4 High
IV Any T N1 M0 Any
IV
Any T N1 M0 Any
Any T Any N M1 Any Any T Any N M1 Any
T — tumour size (T1 — tumour with maximum size 2 cm; T2 — tumour with maximum size > 2 and ≤ 5 cm; T3 — maximum tumour size > 5 and ≤ 10 cm; 
T4 — tumour with maximum size > 10 cm); IM — mitotic index (number of mitotic for 50 HPF: low ≤ 5 or high > 5); N — regional lymph nodes (N0 — absence 
of metastasis; N1 — metastases); M — distant metastasis (M0 — absence of metastases; M1 — metastases); TNM — tumour–node–metastasis
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pecially intraoperative tumour rupture) [46] [I, A]. In 
GIST derived from the stomach, the prognosis is better 
than for localisation in the small or thick intestine. The 
patient should be informed of the possibility of relapse 
after a long period of excision of the primary tumour. 
Patients from groups with high and intermediate de-
grees of aggressiveness, when they are not qualified for 
adjuvant therapy, should be closely monitored by means 
of a CT scan of the abdomen and pelvis contrast every 
3–4 months for the first two years after resection of the 
primary tumour, then every six months to five years after 
the initial surgery, and once a year after five years. The 
same monitoring interval applies to patients after com-
pletion of adjuvant treatment. In the case of low-aggres-
sion GIST resections, control tests can be performed 
once a year (Tab. 10).
Adjuvant therapy
Adjuvant treatment with imatinib for three years 
in patients with high risk of recurrence increases 
relapse-free survival and overall survival compared with 
a schema of one-year therapy [SSGXVIII study] [II, A] 
[47]. The results of the earlier ACOSOG Z9001 trial, 
wherein the adjuvant imatinib was used for a year, led to 
the registration of imatinib in post-operative treatment 
of GIST with a significant risk of recurrence. In light of 
current knowledge, patients with very low or low risk of 
recurrence should not receive adjuvant treatment with 
imatinib. Adjuvant treatment in a group with a high 
risk of recurrence after resection of the primary tumour 
should last for three years. At the same time, at patient 
qualification for the adjuvant treatment, it is manda-
tory to assess the mutation status of GIST — the use 
of adjuvant treatment with imatinib in GIST genotypes 
with low sensitivity to imatinib (PDGFRA D842V or 
wild-type) remains questionable.
The greatest benefit of adjuvant therapy is seen in 
patients at highest risk of relapse (> 5 mitoses/50 HPF 
and/or tumour size > 5 cm, location of the primary 
tumour in other parts of the gastrointestinal tract than 
the stomach, resection within microscopically confirmed 
infiltrated margins surgical — R1, or rupture of the 
tumour during surgery).
Treatment in an advanced stage
Advanced GIST (unresectable or pre-metastatic tu-
mour) are resistant to conventional chemotherapy. The 
value of radiotherapy has not been finally determined, 
although the effects of palliative radiotherapy on locally 
unresectable lesions (pelvis) or bone metastases are 
encouraging. Currently, standard treatment for patients 
with unresectable lesions, recurrent or metastatic, is 
imatinib [I, A].
Current I–III prospective clinical trials for imatin-
ib-inoperable or disseminated GIST have shown that 
complete responses are rarely observed (about 5–7%), 
most often with partial remission (about 50%) and 
stabilisation of the disease (about 36%) and sporadi-
cally primary and early resistance (about 10%), and the 
number of metastases is not relevant for the likelihood 
of achieving response [48, 49]. Longer-term use of 
imatinib in advanced GIST increases the percentage 
of partial responses in patients with stabilisation seen 
in the first months of treatment but is associated with 
a higher rate of progression. The long-term outcome 
of the phase II study (observation > 4 years) showed 
that the median total survival in advanced GIST pa-
tients was about five years, which is about four times 
longer than the historical data (median survival: 
12–15 months). Similar results were published by the 
Polish multicentre group within the framework of the 
GIST Clinical Registry. It is now widely accepted that 
treatment with imatinib should be continued until 
tumour progression (even for several years) because 
discontinuation of therapy may result in rapid progres-
sion of the disease.
Toxicity of treatment occurs in the majority of 
patients, but generally has the severity of grade I or 
II according to the scale of the World Health Organi-
sation — the most common are: anaemia, oedema, 
especially periorbital, weakness, diarrhoea, nausea, 
granulocytopaenia, muscle cramps, and skin rash. Some 
of the symptoms may resolve spontaneously and with-
out interruption of treatment; a significant degree of 
anaemia, with the need to supplement the deficiencies 
of blood is rare (< 15% of patients). Before initiation 
of therapy morphology and biochemical parameters 
of blood should be tested and performance status ac-
cording to the WHO evaluated. During treatment it is 
necessary to monitor the patient for toxicity, especially 
in the initial period of treatment (every two weeks for 
the first month, every month for the next six months, 
and then, in the case of obtaining responses and good 
tolerability, every three months). The patient should 
systematically take imatinib at the recommended daily 
dose. During the treatment, interactions with many 
other drugs (especially metabolised by cytochromes 
liver) should be taken into account.
Table 10. Eligibility criteria for imatinib therapy for patients with 
advanced gastrointestinal stromal tumours (GIST)
Pathological diagnosis of GIST
Positive immunohistochemical result for CD117
Non-resectable lesions and/or metastasis in the CT or MRI
Lesions measurable in CT imaging (MRI)
Performance status 0–3 according to WHO
Preserved absorption from the gastrointestinal tract
Adequate renal and liver function
Obtaining written consent of the patient
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Criteria for the qualification of GIST patients for 
imatinib include relapses following surgery in the form 
of liver metastases and/or intraperitoneal dissection, and 
unresectable primary and/or local recurrences (Tab. 10).
Treatment is started at a dose of 400 mg imatinib 
administered orally at a single dose per day. It is 
now recommended to increase the dose to 800 mg 
(2 × 400 mg/d.) in case of progression. In cases of 
III–IV toxicity, the dose should be reduced to 600 mg 
(2 × 300 mg/d). There are studies that indicate the need 
to initiate treatment with a daily dose of 800 mg in the 
presence of a specific mutation in exon 9 of the KIT gene 
for better progression-free survival. 
The efficacy of imatinib is monitored solely on the 
basis of intravenous and oral contrast-enhanced CT 
(ultrasound is not useful). The first KT study should be 
carried out a few days before the start of treatment, then 
every two months for the first six months of therapy, and 
then every 3–4 months. In some patients, clinical benefit 
is delayed (median time to treatment response: four 
months), and the first complete assessment of response 
to therapy should be performed after four months, 
and at least two further CTs. The primary parameters 
evaluated are the size of tumour changes according to 
the criteria for the response of tumours — Evaluation 
Criteria in Solid Tumours (RECIST) — the sum of 
the longest dimensions of measurable tumours — and 
the determination of the density of lesions (so-called 
Choi criteria). The response should be assessed very 
carefully, which is particularly important in differen-
tiating between stabilisation (inhibition of progres-
sion) and actual progression because patients with 
stable disease as assessed by conventional RECIST 
criteria benefit significantly from treatment (an effect 
similar to that seen in patients with partial response 
to therapy). Caution is advised due to the fact that 
in the early stages of treatment the reduction of the 
density of tumour lesions (e.g. multiple metastases in 
the liver) may result in a false image of “new” lesions 
or an apparent increase in the prevalence of lesions, 
which does not correspond to the progression of the 
disease. The fastest response to the therapy assessment 
can be obtained by PET-CT. 
During the treatment with imatinib some patients 
experience disease progression associated with resist-
ance to the drug (Tab. 11). A small proportion of pa-
tients (10–15%) well qualified for the treatment (GIST 
CD117+) show primary and early resistance during the 
initial six months of treatment. In patients responding 
to the treatment, along with extending the treatment 
duration, secondary (acquired) resistance to imatinib 
can occur. It is estimated that during 2–3 years of treat-
ment with imatinib 40–50% of patients show evidence 
of progressive disease. In imaging studies a limited form 
of progression can be present (e.g. the appearance of 
1–2 lesions with maintained regression of the other me-
tastases or the appearance of a growing nodule within 
necrotic modified metastasis — the so-called “nodule 
within the mass” sign). Generally, however, the features 
of multifocal progression are observed. It was found that 
different mechanisms probably accompany primary and 
secondary resistance, which occurs during treatment 
with imatinib. The most common secondary resistance 
is a result of the acquisition of additional mutation or 
mutations in KIT or PDGFRA, which lead to changes 
in receptor conformation and the inability to bind to 
imatinib. Taking into account the primary molecular 
characterisation of GIST, the best response to imatinib 
is observed in cases of the most common mutation in 
exon 11 (encoding the intracellular membrane area at 
a transmembrane receptor KIT), and much worse results 
in the case of mutation in exon 9 or absence of mutations 
in the KIT gene (sometimes related to the presence of 
mutations in PDGFR, especially D842V) [50] [I, A].
In cases of progression after increasing imatinib 
to a maximum dose of 800 mg [II, A], the use of 
second-line tyrosine kinase inhibitors should be con-
sidered. The use of other inhibitors, acting on different 
points in the metabolic pathway than those associ-
ated with exon 11 KIT mutation, can help overcome 
resistance to imatinib. Currently, the only approved 
drug in the second line with resistance to imatinib or 
intolerance to treatment is sunitinib, which is a mul-
tikinase tyrosine receptor inhibitor working on KIT, 
PDGFR, vascular endothelial growth factor (VEGFR), 
and FLT3. Available data indicate the possibility of 
Table 11. Treatment of advanced gastrointestinal stromal tumour (GIST) after progression during imatinib therapy
In the case of early resistance, verification of diagnosis (including molecular diagnostics)
Increasing the daily dose of imatinib 800 mg (at least stabilisation of the disease in approx. 30% of patients) and a check of other 
medications taken by the patient (e.g. acting on the enzyme system in the liver and changing the concentrations of imatinib in the blood)
In the case of limited progression, it is necessary to consider surgery or ablative approach (continue treatment with imatinib for the 
control of most of the lesions)
The use of sunitinib malate in second-line treatment
In case of further progression regorafenib (optional sorafenib — off label use) in the third line and enrolment of patients to 
prospective clinical trials on new drugs
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Table 12. Recommended follow-up in patients with soft tissue sarcomas (excluding gastrointestinal stromal tumours — GIST)
Stages of treatment Type of examination Frequency of performed tests
After radical treatment of 
GIST with low and very 
low risk of recurrence of 
the disease (stage I)
There are no absolute indications for regular follow-up; 
examination by ultrasound or a CT of the abdomen 
and pelvis once a year may be considered. The patient 
must be informed about the existing low risk of relapse 
a long time after treatment
Annually
After radical treatment of 
GIST intermediate risk of 
recurrence (stage II)
Examination and symptoms, standard CT of the 
abdomen and pelvis with contrast; other tests 
individualised and depending e.g. on the location of the 
primary tumour (e.g. MRI of the pelvis for rectal GIST, 
CT of chest in oesophageal GIST)
Every 3–6 months during the first 2–3 years, 
every 6–12 months up to 5 years after the 
initial surgery, and once a year after 5 years
After radical treatment of 
GIST with a high risk of 
recurrence (grade III)
Examination and symptoms, standard CT of the 
abdomen and pelvis with contrast; other tests 
individualised and depending e.g. on the location of the 
primary tumour (e.g. MRI of the pelvis for rectal GIST, 
CT of chest in oesophageal GIST)
Every 3–4 months for the first 2–3 years, 
every 6 months up to 5 years after the 
initial surgery, and once a year after 5 years 
(in the case of adjuvant treatment with 
imatinib, such a scheme is valid from 
completion of the adjuvant treatment)
After the treatment 
of distant metastases 
(stage IV)
Evaluation in imaging studies, depending on the 
location of measurable metastases — usually CT or 
a MRI of the abdomen and pelvis
Program of control visits for each individual 
patient; during treatment with tyrosine 
kinase inhibitors follow-up is recommended 
every 2–3 months
long-term response in approximately 40% of imatin-
ib-resistant GIST patients, especially in the presence 
of primary mutation in exon 9 or absence of KIT gene 
mutations (e.g. GIST in children). The median time 
to progression of GIST patients treated with sunitinib 
is 6–8 months [I, A] [51, 52]. In the case of sunitinib, 
treatment should be initiated with a daily dose of 50 mg 
in a six-week regimen (four weeks of active treatment 
and two weeks’ pause). In the case of the occurrence 
of toxicity, the daily dose of sunitinib can be reduced 
to 37.5 or 25 mg and there can be extended breaks in 
the regimen. An increasingly widely accepted alterna-
tive is a continuous dosing regimen (37.5 mg every day 
without interruption), which seems more justified in 
the case of tyrosine kinase inhibitors. The side effects 
in grade III–IV toxicity are more frequent than in the 
case of treatment with imatinib, and include mainly the 
occurrence of hand-foot syndrome, fatigue, neutropae-
nia, thrombocytopaenia, diarrhoea, nausea, mucositis, 
hypertension, and hypothyroidism. 
Prolongation of progression-free survival with 
regorafenib in patients with GIST-resistant GIST was 
demonstrated in a prospective, randomised, place-
bo-controlled trial after failure of imatinib and sunitinib 
and is now a registered option within the third line of 
proceedings [I, A] [53]. In Poland it is now possible to 
treat patients after progression on imatinib and suni-
tinib using sorafenib outside the registration indications 
[II, A] [54]. In the case of further progression, it is 
recommended that the patient be included in clinical 
trials with new medications (e.g. BLU-285, DCC-2618, 
crenolanib), which in phase I studies has shown promis-
ing activity also in the case of occurrence of PDGFRA 
D842V mutation.
In the case of symptomatic lesions or rare limited pro-
gression of the disease, local treatment may be considered 
(radiofrequency ablation, surgical resection, chemoem-
bolisation of the hepatic artery branch). In rare cases of 
bone metastases, palliative RTH should be considered. 
In selected cases the resumption of imatinib treatment at 
a daily dose of 400 mg can also be reassessed, which can 
significantly slow the progression of the disease (some 
of the lesions remain susceptible to imatinib treatment). 
A small proportion of total remissions observed in 
imaging studies during imatinib therapy, while increas-
ing the number of patients with progression due to 
secondary mutations and clinically late resistance, lead 
to individualised use of surgical methods to improve 
imatinib treatment outcomes. Surgical treatment with 
tyrosine kinase inhibitors should be planned in patients 
with initially pronounced partial response and subse-
quent stabilisation of two consecutive CT tests (i.e. 
4–6 months) and based on the possibility of resection 
of lesions [III, C] [55]. At the same time, it is necessary 
to continue imatinib and/or sunitinib treatment after 
residual (including radical) resection. Surgical treat-
ment should not be used in cases of multifocal GIST 
progression with imatinib or sunitinib. 
Table 12 presents the recommended screening tests 
for GIST patients.
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